Omixon at the EFI Annual Meeting 2018

07/05/2018

Omixon announce today that Holotype HLA and other Omixon products will be featured in eight poster presentations produced by Holotype customers at the annual meeting of the European Federation for Immunogenetics (EFI) in Venice, Italy. Additionally, Omixon’s Lunch Symposium on Thursday will focus on the experiences of existing Holotype...

Celebrating the Opening of our New Lab in Budapest!

24/04/2018

We are extremely proud to announce the opening of our new lab in Budapest! We spent a couple of months building up a lab that provides all necessary equipment for research and Next Generation Sequencing. This is a huge improvement for our team and thank you all at Omixon...

Omixon Announces Holotype HLA v2 Products are CE Certified

18/04/2018

Omixon has announced that it has received CE Certificate for the v2 protocol of its world leading Holotype HLA Typing Kit. It certifies that all v2 products comply with IVD Directive 98/79/EC to commercialize the new version products as IVD in Europe. Holotype HLA Configurations deliver improved amplification robustness,...

Omixon Welcomes Dan Mancuso as Market Development Director for the Americas

29/03/2018

Omixon is delighted to announce that Dan Mancuso will join Omixon’s US Operations as a new Market Development Director, Americas, effective April 2, 2018. About Dan With 30 years of experience in the HLA field, Dan is excited to join the Omixon team and begin his new role as...

Omixon is Now ISO Certified for Canada

26/03/2018

Omixon announce its Quality Management System complies with the requirements of ISO 13485:2003 certified by a CMDCAS recognised registrar. As a result Omixon’s QMS meets the Canadian Medical Devices Regulations for design, development, manufacture and distribution, servicing and customer support of In Vitro diagnostic reagents, kits and software...